● Recruiting

Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure

Condition: Chronic Kidney Disease · Heart Failure With Reduced Ejection Fraction (HFrEF) · Sponsor: Evi Liliek Wulandari

PhasePhase 4

Planned participants80

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Evi L Wulandari, MD., Internist · (+62)821-3587-2749 · evililiek@staff.uns.ac.id

Always discuss trial participation with your own doctor first.

Locations (1)

UNS Hospital

Kartasura, Central Java, Indonesia

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07259512